MedPath

Detoxification From the Lipid Tract

Phase 4
Completed
Conditions
COVID-19 Vaccine Adverse Reaction
Interventions
Device: electroencephalogram biofeedback
Device: electrical brain stimulation
Device: ultra-low frequency transcranial magnetic stimulation
Registration Number
NCT06357104
Lead Sponsor
Pachankis, Yang I., M.D.
Brief Summary

Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid (GABA) stimulation. The cocktail therapy starts after the primary efficacy endpoint, and concomitant therapy is adopted throughout the study.

Detailed Description

It was tested that GABA, in the joint action with topiramate, modulates macrophage activities by modulating cholesterol-metabolism associated molecules. GABA A receptors exhibit highly dynamic trafficking and cell surface mobility and influence on post-endocytic effects. Benzodiazepines (BZDs) exercise the mechanism of action by facilitating the binding of the inhibitory neurotransmitter GABA at various GABA receptors throughout the central nervous system (CNS). Alprazolam, a type of BZD, was tested by Al-Tubuly, Aburawi, Alghzewi, Gorash and Errwami in joint action with water-soluble beta blocker atenolol, in comparison with the non-selective β-adrenoceptor antagonist propranolol on the pharmacological effects on depression. The study hypothesizes that by replacing the water-soluble beta blocker to lipid-soluble one metoprolol, the effect of detoxification from the lipid and sebaceous immunobiological pathways can be achieved by the clathrin-dependent endocytosis process.

Even though partial progress was made in the NCT05839236 trial by statin therapies, the therapeutic effects have not been lasting nor significant. The study develops from the previous protocol for a cocktail therapy by the joint mechanism of actions of alprazolam, metoprolol, and pravastatin sodium for the detoxification process.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • People who received full doses of COVID-19 vaccines.
Exclusion Criteria
  • Women during pregnancy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
GABA Cocktailelectroencephalogram biofeedback-
GABA Cocktailelectrical brain stimulation-
GABA Cocktailultra-low frequency transcranial magnetic stimulation-
GABA CocktailSertraline Hydrochloride-
GABA CocktailClonazepam-
GABA CocktailPravastatin Sodium 20 MG-
GABA CocktailSacubitril Valsartan Sodium Hydrate-
GABA CocktailAlprazolam-
GABA CocktailOlanzapine-
GABA CocktailMetoprolol-
Primary Outcome Measures
NameTimeMethod
Changes in Leukocyte and Components' Quantities24 days

All white blood cells are evaluated.

Changes in Leukocyte Components' Ratios24 days

All white blood cells are evaluated.

Quantity Changes in Megakaryocyte-Erythroid Progenitor24 days
Changes in Hemoglobin Distribution24 days
Changes in Mean Corpuscular Hemoglobin24 days
Changes in Hematocrit24 days
Changes in Plateletcrit24 days
Red cell Distribution Width Coefficient of Variation24 days
Changes in Particulate Matter Sizes24 days
Changes in Total Lipid Quantities24 days
Changes in Apolipoproteina24 days
Changes in Lipoprotein (a)24 days
Secondary Outcome Measures
NameTimeMethod
Heart Rate Changes24 days

Heart rate changes before and after medication each day.

Blood Pressure Changes24 days

Recorded systolic and diastolic blood pressures' changes before and after medication each day.

Trial Locations

Locations (1)

Residential Address

🇨🇳

Chongqing, Chongqing, China

© Copyright 2025. All Rights Reserved by MedPath